NEW YORK (GenomeWeb News) – EKF Diagnostics this week said it completed its acquisitions of Selah Genomics and DiaSpect Medical. When the deals were announced last month, EKF said the Selah acquisition comprises an initial consideration of $35.6 million through the issue of new EKF shares and an additional deferred consideration of up to $35 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.